Tower Research Capital (TRC)’s Kyntra Bio KYNB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.4K | Buy |
1,113
+781
| +235% | +$5.48K | ﹤0.01% | 4076 |
|
|
2026
Q1 | $2.25K | Buy |
332
+116
| +54% | +$908 | ﹤0.01% | 4510 |
|
|
2025
Q4 | $1.9K | Sell |
216
-72
| -25% | -$704 | ﹤0.01% | 4619 |
|
|
2025
Q3 | $3.53K | Sell |
288
-505
| -64% | -$4.74K | ﹤0.01% | 4490 |
|
|
2025
Q2 | $4.2K | Buy |
+793
| New | +$5.78K | ﹤0.01% | 4364 |
|
|
2025
Q1 | – | Sell |
-305
| Closed | -$4.04K | – | 5379 |
|
|
2024
Q4 | $4.04K | Buy |
+305
| New | +$2.83K | ﹤0.01% | 4535 |
|
|
2024
Q3 | – | Sell |
-711
| Closed | -$15.9K | – | 5794 |
|
|
2024
Q2 | $15.9K | Sell |
711
-136
| -16% | -$4.2K | ﹤0.01% | 3890 |
|
|
2024
Q1 | $49.7K | Buy |
847
+293
| +53% | +$12.6K | ﹤0.01% | 2278 |
|
|
2023
Q4 | $12.3K | Buy |
554
+72
| +15% | +$1.09K | ﹤0.01% | 4059 |
|
|
2023
Q3 | $10.4K | Sell |
482
-281
| -37% | -$11K | ﹤0.01% | 4114 |
|
|
2023
Q2 | $51.5K | Buy |
763
+628
| +465% | +$260K | ﹤0.01% | 2559 |
|
|
2023
Q1 | $63K | Buy |
135
+94
| +229% | +$49.7K | ﹤0.01% | 2295 |
|
|
2022
Q4 | $16K | Sell |
41
-519
| -93% | -$199K | ﹤0.01% | 3342 |
|
|
2022
Q3 | $182K | Sell |
560
-27
| -5% | -$8.7K | ﹤0.01% | 2027 |
|
|
2022
Q2 | $155K | Buy |
587
+119
| +25% | +$30.4K | ﹤0.01% | 1959 |
|
|
2022
Q1 | $140K | Buy |
468
+42
| +10% | +$14.6K | ﹤0.01% | 1980 |
|
|
2021
Q4 | $151K | Sell |
426
-97
| -19% | -$30.2K | ﹤0.01% | 1969 |
|
|
2021
Q3 | $134K | Buy |
523
+285
| +120% | +$101K | ﹤0.01% | 2148 |
|
|
2021
Q2 | $159K | Sell |
238
-174
| -42% | -$100K | ﹤0.01% | 2089 |
|
|
2021
Q1 | $357K | Buy |
412
+206
| +100% | +$219K | 0.01% | 1518 |
|
|
2020
Q4 | $191K | Sell |
206
-80
| -28% | -$84.1K | 0.01% | 1747 |
|
|
2020
Q3 | $294K | Sell |
286
-146
| -34% | -$157K | ﹤0.01% | 2208 |
|
|
2020
Q2 | $438K | Buy |
+432
| New | +$401K | 0.02% | 1139 |
|
|
2020
Q1 | – | Sell |
-236
| Closed | -$253K | – | 3296 |
|
|
2019
Q4 | $253K | Buy |
+236
| New | +$241K | 0.02% | 493 |
|
|
2019
Q3 | – | Sell |
-2
| Closed | -$2K | – | 4215 |
|
|
2019
Q2 | $2K | Sell |
2
-25
| -93% | -$27.4K | ﹤0.01% | 3263 |
|
|
2019
Q1 | $36K | Buy |
27
+23
| +575% | +$31.2K | ﹤0.01% | 1934 |
|
|
2018
Q4 | $4K | Sell |
4
-25
| -86% | -$28.1K | ﹤0.01% | 3022 |
|
|
2018
Q3 | $43K | Buy |
+29
| New | +$44.7K | ﹤0.01% | 1847 |
|
|
2018
Q1 | – | Sell |
-7
| Closed | -$9K | – | 3436 |
|
|
2017
Q4 | $9K | Sell |
7
-175
| -96% | -$219K | ﹤0.01% | 2607 |
|
|
2017
Q3 | $245K | Buy |
182
+168
| +1,200% | +$177K | 0.02% | 618 |
|
|
2017
Q2 | $11K | Buy |
+14
| New | +$9.75K | ﹤0.01% | 1560 |
|
|
2017
Q1 | – | Sell |
-105
| Closed | -$56K | – | 3305 |
|
|
2016
Q4 | $56K | Buy |
105
+101
| +2,525% | +$50.4K | 0.01% | 1355 |
|
|
2016
Q3 | $2K | Buy |
+4
| New | +$1.88K | ﹤0.01% | 3068 |
|
|
2016
Q1 | – | Sell |
-8
| Closed | -$6K | – | 4364 |
|
|
2015
Q4 | $6K | Sell |
8
-13
| -62% | -$8.63K | ﹤0.01% | 2760 |
|
|
2015
Q3 | $12K | Buy |
21
+13
| +163% | +$7.88K | ﹤0.01% | 2151 |
|
|
2015
Q2 | $5K | Sell |
8
-22
| -73% | -$12.8K | ﹤0.01% | 3238 |
|
|
2015
Q1 | $23K | Buy |
+30
| New | +$23.3K | ﹤0.01% | 2136 |
|
Other funds holding KYNB
AC
BC
Tower Research Capital (TRC)'s KYNB Position: Q2 2026 in Review
Tower Research Capital (TRC) increased its Kyntra Bio (KYNB) stake by 235% in Q2 2026, buying an estimated $5.48K and bringing the position to 1,113 shares worth $8.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4076.
Tower Research Capital (TRC) first reported a position in KYNB in Q1 2015 and has held it in 37 quarters since. The position peaked at $438K in Q2 2020. 27 funds tracked by Wall St. Rank hold KYNB as of Q2 2026.
- Tower Research Capital (TRC) held 1,113 shares of Kyntra Bio worth $8.4K as of Q2 2026.
- Tower Research Capital (TRC) bought 781 Kyntra Bio shares in Q2 2026, an estimated $5.48K.
- Kyntra Bio made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4076 holding.
- Tower Research Capital (TRC) first reported a position in Kyntra Bio in Q1 2015 and has held it in 37 quarters since.
- Tower Research Capital (TRC)'s Kyntra Bio position peaked at $438K in Q2 2020.
- 27 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.